Pendopharm Secures AMC Reimbursement Nod for Yorvipath

For manufacturers navigating Canada's post-authorization reimbursement landscape, Pendopharm's Yorvipath® (palopegteriparatide injection) has cleared a critical HTA checkpoint: Canada's Drug Agency (CDA-AMC) has issued a conditional recommendation to reimburse the therapy through participating public drug plans for eligible adults with chronic hypoparathyroidism inadequately controlled by conventional treatment.

Health Canada authorized palopegteriparatide on January 28, 2026, as a parathyroid hormone (PTH) replacement therapy for adults with chronic hypoparathyroidism. The CDA-AMC review drew on evidence from the Phase 3 PaTHway clinical trial, which evaluated the drug in this patient population. The conditional nature of the recommendation reflects standard CDA-AMC practice: participating federal, provincial, and territorial drug plans retain independent authority over final listing decisions, meaning the reimbursement pathway remains open but unresolved at the jurisdictional level.

For regulatory affairs and market access teams, the sequencing here is instructive. Health Canada authorization preceded the HTA submission, and the CDA-AMC recommendation now triggers a separate negotiation and listing process across multiple payer jurisdictions, a multi-step model that is increasingly the norm for rare endocrine disease therapies in Canada. Pendopharm, a specialty division of Pharmascience Inc., is commercializing the product under license from Ascendis Pharma A/S, which holds the Yorvipath trademark through its Bone Diseases subsidiary.

Clinically, the recommendation targets a defined population: adults for whom oral calcium and active vitamin D, the guideline-recommended first-line approach, have proven inadequate. PTH replacement is positioned as a second-line option addressing the underlying hormone deficiency rather than managing downstream calcium dysregulation. Dr. Aliya Khan, Director of the Calcium Disorders Clinic at McMaster University, noted that conventional therapy leaves some patients with significant daily burden despite intensive supplementation regimens.

The conditional reimbursement recommendation advances Yorvipath toward public drug plan listing discussions, with each jurisdiction's final decision representing the next measurable outcome in the Canadian access timeline.

Source: Pendopharm via GlobeNewswire, September 3, 2026.